GOVX GeoVax Labs, Inc.
GeoVax Labs, Inc. (GOVX) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $24.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.3% since its last earnings release on November 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About GeoVax Labs, Inc.
GeoVax Labs, Inc., is a development stage biotechnology company. It is engaged in developing human vaccines for diseases caused by Human Immunodeficiency Virus (HIV).
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.